1. Home
  2. TRNI vs AAPG Comparison

TRNI vs AAPG Comparison

Compare TRNI & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRNI

Trinity Capital Inc. 7.875% Notes Due 2029

N/A

Current Price

$25.32

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

AAPG

Ascentage Pharma Group International American Depository Shares

HOLD

Current Price

$17.00

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRNI
AAPG
Founded
N/A
2009
Country
United States
China
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
2020
2024

Fundamental Metrics

Financial Performance
Metric
TRNI
AAPG
Price
$25.32
$17.00
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$48.40
AVG Volume (30 Days)
8.5K
4.3K
Earning Date
N/A
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.85
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$290.34
Revenue Next Year
N/A
N/A
P/E Ratio
$29.76
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.21
$16.36
52 Week High
$25.38
$45.90

Technical Indicators

Market Signals
Indicator
TRNI
AAPG
Relative Strength Index (RSI) 53.40 42.32
Support Level $25.22 $16.62
Resistance Level $25.36 $18.17
Average True Range (ATR) 0.07 0.53
MACD 0.00 -0.06
Stochastic Oscillator 64.71 33.34

Price Performance

Historical Comparison
TRNI
AAPG

About AAPG Ascentage Pharma Group International American Depository Shares

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.

Share on Social Networks: